Literature DB >> 32900788

The Pathological Evolution of Glucose Response Curves During the Progression to Type 1 Diabetes in the TrialNet Pathway to Prevention Study.

Heba M Ismail1, Mario A Cleves2, Ping Xu2, Ingrid M Libman3, Dorothy J Becker3, Jennifer B Marks4, Jay S Skyler4, Jerry P Palmer5,6, Jay M Sosenko4.   

Abstract

OBJECTIVE: Glucose response curves (GRCs) during oral glucose tolerance tests (OGTTs) are predictive of type 1 diabetes. We performed a longitudinal analysis in pancreatic autoantibody-positive individuals to assess 1) characteristic GRC changes during progression to type 1 diabetes and 2) GRC changes in relation to β-cell function changes and to combined glucose and C-peptide response curve (GCRC) changes. RESEARCH DESIGN AND METHODS: Among antibody-positive individuals with serial OGTTs in the TrialNet Pathway to Prevention study, GRC changes from first to last OGTTs were compared between progressors (n = 298) to type 1 diabetes and nonprogressors (n = 2,216). GRC changes from last OGTT before diagnosis to diagnostic OGTTs were studied in progressors.
RESULTS: GRCs changed more frequently from biphasic (two peaks) to monophasic (one peak) GRCs between first and last OGTTs in progressors than in nonprogressors (75.4% vs. 51.0%, respectively; P < 0.001). In contrast, GRCs of progressors changed less frequently from monophasic to biphasic than those of nonprogressors (12.6% vs. 30.6%; P < 0.001). Monotonic (continuous increase) GRCs were present in 47.7% of progressors at diagnosis. The early (30-0 min) C-peptide response decreased in progressors with GRCs changing from biphasic to monophasic between first and last OGTTs (P < 0.001) and from monophasic to monotonic between last and diagnostic OGTTs (P < 0.001). Conversely, the early C-peptide response increased among nonprogressors with GRCs changing from monophasic to biphasic (P < 0.001). Changes in GRCs were related to changes in GCRCs.
CONCLUSIONS: Characteristic GRC changes, biphasic to monophasic to monotonic, occur during the progression to type 1 diabetes. These GRC changes correspond to decreasing β-cell function.
© 2020 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32900788      PMCID: PMC7576415          DOI: 10.2337/dc20-0701

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  17 in total

1.  Assessing the shape of the glucose curve during an oral glucose tolerance test.

Authors:  Otto Tschritter; Andreas Fritsche; Fatemeh Shirkavand; Fausto Machicao; Hans Häring; Michael Stumvoll
Journal:  Diabetes Care       Date:  2003-04       Impact factor: 19.112

2.  Report of the expert committee on the diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

3.  Beta-cell function and insulin sensitivity contribute to the shape of plasma glucose curve during an oral glucose tolerance test in non-diabetic individuals.

Authors:  M Kanauchi; K Kimura; K Kanauchi; Y Saito
Journal:  Int J Clin Pract       Date:  2005-04       Impact factor: 2.503

4.  Insulinogenic indices from insulin and C-peptide: comparison of beta-cell function from OGTT and IVGTT.

Authors:  Andrea Tura; Alexandra Kautzky-Willer; Giovanni Pacini
Journal:  Diabetes Res Clin Pract       Date:  2005-12-01       Impact factor: 5.602

5.  Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study.

Authors:  Muhammad A Abdul-Ghani; Christopher P Jenkinson; Dawn K Richardson; Devjit Tripathy; Ralph A DeFronzo
Journal:  Diabetes       Date:  2006-05       Impact factor: 9.461

6.  Shape of glucose, insulin, C-peptide curves during a 3-h oral glucose tolerance test: any relationship with the degree of glucose tolerance?

Authors:  Andrea Tura; Umberto Morbiducci; Stefano Sbrignadello; Yvonne Winhofer; Giovanni Pacini; Alexandra Kautzky-Willer
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-01-19       Impact factor: 3.619

7.  The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test: Forerunner of Heightened Glycemic Failure Rates and Accelerated Decline in β-Cell Function in TODAY.

Authors:  Silva Arslanian; Laure El Ghormli; Joon Young Kim; Fida Bacha; Christine Chan; Heba M Ismail; Lorraine E Levitt Katz; Lynne Levitsky; Jeanie B Tryggestad; Neil H White
Journal:  Diabetes Care       Date:  2018-11-19       Impact factor: 19.112

8.  The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test Heralds Biomarkers of Type 2 Diabetes Risk in Obese Youth.

Authors:  Joon Young Kim; Sara F Michaliszyn; Alexis Nasr; SoJung Lee; Hala Tfayli; Tamara Hannon; Kara S Hughan; Fida Bacha; Silva Arslanian
Journal:  Diabetes Care       Date:  2016-06-12       Impact factor: 19.112

9.  Glucose response curve and type 2 diabetes risk in Latino adolescents.

Authors:  Joon Young Kim; Dawn K Coletta; Lawrence J Mandarino; Gabriel Q Shaibi
Journal:  Diabetes Care       Date:  2012-06-29       Impact factor: 19.112

10.  Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Authors:  Jay M Sosenko; Jerry P Palmer; Lisa E Rafkin; Jeffrey P Krischer; David Cuthbertson; Carla J Greenbaum; George Eisenbarth; Jay S Skyler
Journal:  Diabetes Care       Date:  2009-12-23       Impact factor: 17.152

View more
  5 in total

1.  The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes.

Authors:  Emily K Sims; David Cuthbertson; Kevan C Herold; Jay M Sosenko
Journal:  Diabetes       Date:  2021-09-22       Impact factor: 9.461

Review 2.  Transforming type 1 diabetes: the next wave of innovation.

Authors:  Daniel J Drucker
Journal:  Diabetologia       Date:  2021-02-06       Impact factor: 10.122

3.  Shape of the OGTT glucose response curve: relationship with β-cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin.

Authors:  Kristina M Utzschneider; Naji Younes; Neda Rasouli; Joshua I Barzilay; Mary Ann Banerji; Robert M Cohen; Erica V Gonzalez; Faramarz Ismail-Beigi; Kieren J Mather; Philip Raskin; Deborah J Wexler; John M Lachin; Steven E Kahn
Journal:  BMJ Open Diabetes Res Care       Date:  2021-09

4.  Mechanistic Insights Into the Heterogeneity of Glucose Response Classes in Youths With Obesity: A Latent Class Trajectory Approach.

Authors:  Domenico Tricò; Sarah McCollum; Stephanie Samuels; Nicola Santoro; Alfonso Galderisi; Leif Groop; Sonia Caprio; Veronika Shabanova
Journal:  Diabetes Care       Date:  2022-08-01       Impact factor: 17.152

5.  Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample.

Authors:  Naiara G Bediaga; Connie S N Li-Wai-Suen; Michael J Haller; Stephen E Gitelman; Carmella Evans-Molina; Peter A Gottlieb; Markus Hippich; Anette-Gabriele Ziegler; Ake Lernmark; Linda A DiMeglio; Diane K Wherrett; Peter G Colman; Leonard C Harrison; John M Wentworth
Journal:  Diabetologia       Date:  2021-08-02       Impact factor: 10.122

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.